Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PAT-048 is an effective and selective autotaxin inhibitor. PAT-048 reduces dermal fibrosis in vivo. PAT-048 also inhibits IL-6 mRNA expression but displays no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in the lung fibrosis model. PAT-048 has an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 383,500 |
50 mg | 約6-8 週間 | ¥ 500,500 |
100 mg | 約6-8 週間 | ¥ 643,000 |
説明 | PAT-048 is an effective and selective autotaxin inhibitor. PAT-048 reduces dermal fibrosis in vivo. PAT-048 also inhibits IL-6 mRNA expression but displays no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in the lung fibrosis model. PAT-048 has an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. |
ターゲット&IC50 | ATX (mouse plasma): 200 nM(IC90), ATX (mouse plasma):20 nM |
分子量 | 461.91 |
分子式 | C22H18ClF2N3O2S |
CAS No. | 1359983-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PAT-048 1359983-15-5 Metabolism PDE PAT 048 PAT048 Inhibitor inhibitor inhibit